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Abstract 
Understanding genetic factors that contribute to cannabis use disorder (CUD) is important, but to 
date, findings have been equivocal. Single nucleotide polymorphisms (SNPs) in the Cannabinoid 
receptor 1 gene (CNR1; rs1049353, rs806378) and Fatty Acid Amide Hydrolase (FAAH) gene (rs324420) 
have been implicated in CUD. Their relationship to addiction endophenotypes such as cannabis-
related state satiety, the salience of appetitive cues and craving after acute cannabinoid 
administration has not been investigated. Forty-eight cannabis users participated in a double-blind, 
placebo-controlled, four-way crossover experiment where they were administered 4 treatments in a 
randomised order via vaporisation: placebo, Δ9-tetrahydrocannabinol (THC) (8mg), THC+Cannabidiol 
(THC+CBD) (8mg + 16mg), CBD (16mg). Cannabis-related state satiety, appetitive cue salience 
(cannabis, food), and cannabis craving were assessed each day. Participants were genotyped for 
rs1049353, rs806378 and rs324420. Results indicated CNR1 rs1049353 GG carriers showed increased 
state satiety after THC/THC+CBD administration, in comparison to placebo and reduced the salience 
of appetitive cues after THC in comparison to CBD administration; A carriers did not vary on either of 
these measures indicative of a vulnerability to CUD. CNR1 rs806378 CC carriers showed greater 
salience to appetitive cues in comparison to T carriers but there was no evidence for changes in state 
satiety. FAAH rs324420 A carriers showed greater bias to appetitive cues after THC, in comparison to 
CC carriers. FAAH CC carriers showed reduced bias after THC in comparison to CBD. No SNPs 
modulated craving. These findings identify candidate neurocognitive mechanisms through which 
endocannabinoid system genetics may influence vulnerability to CUD.  
 
 
Keywords: addiction; cannabis; CBD; craving; THC; endophenotype; salience; addiction 
 
 
 
 
 
 
 
 
 
 
3 
 
 
Introduction 
Problematic drug use is influenced by both environmental and genetic factors with genetic variation 
accounting for ~40 to 60% of the variance of the total risk in vulnerable individuals(1). Policies 
regarding cannabis use worldwide are becoming more liberal. Investigating individual differences in 
the vulnerability and resilience to the harmful effects of cannabis has become a priority area of 
research.  This is particularly important because cannabis currently stands poised to join alcohol and 
tobacco as a legal drug across the globe, meaning rates of cannabis use disorders (CUDs) may also rise. 
CUDs account for the largest global burden of disease related to cannabis(2). The endocannabinoid 
system is fundamental in drug use/abuse(3). Genetic differences in the endocannabinoid system may 
contribute to an individual’s vulnerability or resilience to cannabis dependence.  
The primary psychoactive cannabinoid in cannabis, Δ9-tetrahydrocannabinol (THC), is a partial agonist 
at the cannabinoid receptor type 1 (CB1R). Using cannabis can lead to the development of CUD which 
affects ~9% of those who initiate use(4). The percentage of THC in cannabis has been increasing over 
the past two decades mirroring increased demand for treatment for CUD(5). Cannabidiol (CBD), the 
second most abundant cannabinoid found in many  cannabis plants is neither intoxicating(6) nor 
rewarding(7) and has several psychopharmacologically opposite effects to THC, but its mechanism of 
action has not fully been determined(8). CBD acts as a negative allosteric modulator of the CB1R; 
and/or increases the inhibition of fatty acid amide hydrolase (FAAH); the main degradative enzyme of 
anandamide, thus indirectly regulating the activity of the CB1R. The ratio of THC:CBD is important as 
CBD protects against the development of  CUD and psychotic-like effects of THC(9-11). Moreover, 
preparations of CBD are commonly used alone and are available commercially, therefore it is 
important to investigate the interaction between CBD and genetic variation in the endocannabinoid 
system.  
The CNR1 gene encodes CB1R and is located on chromosome 1(12). Meta-analyses have found that 
polymorphisms in CNR1 have been associated with cannabis, alcohol, nicotine and cocaine 
dependence(12, 13). These polymorphisms are also associated with potential CUD endophenotypes 
such as functional reward-related brain activity during exposure to cannabis cues(14). As such, genetic 
influences may therefore alter other mechanisms related to CUD – such as craving, satiation and drug-
cue salience.  
Endocannabinoid signalling is terminated by enzymes such as FAAH. FAAH inhibition is a mechanism 
that is currently being investigated as a treatment of CUD in humans(15, 16). The rs324420 Single 
Nucleotide Polymorphism (SNP) of the FAAH enzyme is a C to A polymorphism which results in a 
proline to a threonine substitution at codon 129(12). Those with the A allele have reduced FAAH 
expression (17, 18). This reduction has been associated with problematic cannabis use(17, 19) and 
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putative endophenotypes such as craving and withdrawal after short-term abstinence(20). However, 
the C allele has also been associated with cannabis dependence in Genome Wide Association Studies 
(GWAS) (19) as well as other potential endophenotypes such as greater craving and withdrawal after 
short-term abstinence (20, 21). Filbey, et al. (14) found that those who were homozygous for the C 
allele showed greater activation in reward circuitry (which included the orbitofrontal cortex, anterior 
cingulate gyrus and the nucleus accumbens) after a cannabis cue reactivity paradigm, in comparison 
to A allele carriers. However, no studies have investigated how genes related the endocannabinoid 
system predict CUD-related endophenotypes after controlled acute administration of cannabinoids.  
Our innovative approach was to study, in depth, the neurocognitive endophenotypes of CUD after 
acute cannabinoid administration, which may be more valid than a single dichotomous variable such 
as a diagnosis of CUD itself(22). We focussed upon three endophenotypes of CUD which are distinct 
but related processes in CUD. Firstly, attentional processing is an important transdiagnostic marker 
for depression, anxiety and drug dependence(15, 23). THC:CBD ratio predicts attentional bias to 
cannabis cues when intoxicated, with those using more CBD in their cannabis strains showing reduced 
attentional bias (9). The salience of appetitive cannabis stimuli is also related to frequency of cannabis 
use; dependence on the drug itself, and craving(24-26). Secondly, craving, or the intense desire for a 
reward, is a primary behavioural component of CUD which motivates drug use and predicts cannabis 
use after 6 months in adults and adolescents(27, 28). Thirdly, cannabis-related satiety after acute 
ingestion of the drug is a key element of CUD. In line with common theories of addiction(29), after 
acute intoxication, there is reduced incentive value of cannabis i.e. satiety temporarily devalues the 
rewarding effect of cannabis and reduces “wanting” which would be evidenced by an increase in 
reported state satiety, a reduction in craving and attentional bias to drug cues. Therefore, when these 
related processes are unaffected by acute intoxication then this is a key indicator of CUD. Satiety is 
related to loss of control and tolerance measures which is reflected in DSM-5 CUD criterion “taking 
the drug in larger amounts for longer than intended”(30).  
 Our primary aim was to investigate if and how genetic variants in the endocannabinoid system, in 
particular the CB1 receptor (rs1049353 and rs806378) and the FAAH enzyme (rs324420) would 
modulate the acute response to cannabinoids, in relation to promising endophenotypes: cannabis-
related satiation, the salience of appetitive cues and craving. To this end, in this preliminary candidate 
gene investigation, we carried out a randomised, double-blind, crossover study where participants 
were administered THC(8 mg), THC(8 mg)+CBD(16 mg), CBD(16 mg) and placebo (ethanol vehicle) 
across four separate sessions. We hypothesise that CNR1 rs1045393 A allele carriers (versus G 
carriers), rs806378 T carriers (versus C carriers) and FAAH 324420 C carriers (versus A carriers) would 
show greater indicators of CUD which would be evidenced by greater drug cue salience, lower 
satiation and greater craving after intoxication with THC. Moreover, given research that suggests that 
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CBD protects against the dependence-related effects of THC (Morgan et al 2010), differential effects 
of drug conditions were expected on CUD-endophenotypes, although how this would interact with 
genotype was exploratory, given the paucity of research in this area. The main outcome of interest 
was interactions between drug and genotype.  
Material and Methods 
Participants  
Forty-eight participants were recruited for the acute drug challenge study on the basis of having 
previously volunteered in a large scale study of over 400 cannabis users where genotyping was 
conducted(31). Participants were aged between 16 and 23 years wherein participants had a wide 
range of cannabis exposure from 1 day per month to daily use and were recruited via word of mouth 
and snowball sampling(11). Participants for this study were recruited based on 1) schizotypy as 
measured by the Schizotypal Personality Questionnaire score (top and bottom quartiles) and 2) 
Frequency of cannabis use (“light”=1-24 days per month; “heavy”=25+ days per month). This study is 
a secondary analysis concerned with genetic associations across the whole sample regardless of sub-
group. For this study, which had a sample size of 48, we conducted a sensitivity power analysis (32) 
for a repeated measures ANOVA (within-between interaction) which showed we had 80% power to 
detect a small-to-medium effect size (Cohen’s d=0.34) at an alpha of 0.05 with 2 groups, 4 measures 
and an r=0.5 between measures. Additional data from this study on facial affect recognition and visual 
analogue scales(6) and psychotomimetic symptoms and memory function have been reported 
elsewhere(33). 
Participants were matched for age and Spot the Word score (as a correlate of premorbid verbal IQ) 
(34) scores across frequency groups. Inclusion criteria were: (i)self-reported abstinence (confirmed 
with saliva and urinary tests on each experimental day) from cannabis, other drugs and alcohol use 
for 24h prior to each test day; (ii)English fluency, (iii)normal/corrected to normal vision. Exclusion 
criteria were: current self-reported (i)respiratory/physical health problems, (ii)pregnancy or the risk 
of being pregnant, (iii)clinically diagnosed learning impairments, (iv)clinically diagnosed 
schizophrenia/psychosis or substance abuse problems, and (v)illicit drug use other than cannabis more 
than once a week. 
Design 
A four session, randomised, double-blind crossover design was used to compare the acute effects of 
THC (8mg), CBD (16mg) and their combination (8mg THC+16mg CBD) with placebo (ethanol vehicle). 
Both cannabinoids were formulated in alcohol solution and were purchased from STI Pharmaceuticals 
(Brentwood, Essex, UK). Treatment order across the 4 sessions was determined by a balanced Latin 
square resulting in 12 combinations.  
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Drug administration 
Cannabinoids and placebo (ethanol vehicle) were administered using a Volcano Medic Vaporisor 
(Storz & Bickel, Tuttlingen, Germany). 8mg THC dissolved in ethanol and 16mg of CBD dissolved in 
ethanol were administered on a 10-second inhalation cycle wherein participants was instructed to 
first fully exhale, next fully inhale from the balloon, hold their breath for 10 seconds and then fully 
exhale; this was repeated until the balloon was empty. This inhaled dose of THC has been found to 
produce effects on human brain and behaviour, including psychotic-like symptoms, memory 
impairment and cannabis reward processing(35, 36). The 2:1 ratio of CBD:THC reflects the upper limit 
(mean+ 3 SD) found in high CBD/low THC cannabis preparations in the UK(37). Detailed information 
about  concealment and blinding can be found in Hindocha, et al. (6) and Morgan et al.(33). 
Genotyping 
DNA was obtained from cheek swabs of all participants who completed the assessments described 
above. DNA extraction was performed using standard phenol–chloroform methods. Analyses were 
performed on two SNPs of CNR1: rs1049353, rs806378 and one single-nucleotide polymorphism of 
the FAAH gene (rs324420). Off the shelf Taqman assays for these polymorphisms are available as a kit 
(Applied Biosystems, Life Technologies, Paisley, UK). Genotype calls were discriminated on the basis 
of algorithmic membership of three clusters representing homozygote A/A, heterozygote A/G, and 
homozygote G/G genotype classes for CNR1 rs1049353, C/C, C/T and T/T for CNR1 rs806378 and 
CC/AC/AA for FAAH rs324420. Individuals with the minor allele of these SNPS were combined for 
power and due to the rarity of these alleles. For rs1049353, those with the minor allele of A, were 
combined with heterozygotes AG according to convention(38). For CNR1 rs806378, those with the 
minor allele T were combined with heterozygotes CT  and for FAAH rs324420, the minor allele A, was 
combined with the heterozygote AC. Data was missing for 6 individuals for rs1049353, 3 individuals 
for rs806378 and 4 individuals for rs324420. 
Baseline Assessments 
Under non-intoxicated conditions, participants completed the Beck Depression Inventory(39), 
Spielberger Trait Anxiety Inventory(40), Schizotypal Personality Questionnaire(41), Severity Of 
Dependence Scale(42) and a drug history(6, 33) (see table 1).  
Assessment of Endophenotypes   
Bodily Symptoms Scale (BSS)(43): “want to smoke a joint” single item to assess state satiation.  
The BSS was designed to detect physical symptoms of acute cannabinoids administration. Participants 
rated on scale from 0 (do not want to smoke a joint) to 10 (really want a joint), how much they wanted 
to smoke a joint. This measure was assessed twice, both 10 and 70 minutes post-drug administration 
(taking approximately 2 minutes). This measure was used to index state satiation. 
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Dot Probe task (Fig 1) 
Adapted from Morgan, et al. (9), this computer-based dot-probe paradigm was used to assess 
attentional bias to both cannabis- and food-related stimuli. Ten colour photographs of cannabis-
related stimuli and 10 colour photographs of food-related stimuli were used, with each image 
simultaneously paired with a neutral photograph matched as closely as possible for visual composition 
and complexity. A total of 80 of the 160 total trials were critical trials of which 40 featured cannabis-
related and 40 food-related stimuli, each presented twice for 250ms. Only the short exposure time 
was chosen to index automatic (250ms) processing. The critical (food- or cannabis-related) images 
appeared once on the left and once on the right at each time interval. The side at which the probe 
appeared was counterbalanced across all the trials. An asterisk was used as the probe. A total of 10 
neutral practice trial pairs were used as training, followed by two blocks of 80 experimental trials. 
Short break occurred between blocks. Versions were randomised across testing days. Each trial began 
with a central fixation cross shown for 1000ms, after which a pair of matched images would appear, 
one on each side of the fixation cross, for 250ms durations. Both images then disappeared revealing 
the probe behind one of the two images. Participants were required to respond to the probe as quickly 
as possible by pressing a button corresponding to the relevant side of the screen. The task took place 
approximately 25 minutes after drug administration and lasted approximately 10 minutes. Attentional 
bias was calculated as the difference in reaction time between when the probe replaced the neutral 
compared with the incentive (cannabis/food) stimulus [Rtneutral-RTincentive], such that a greater 
difference indicated greater bias toward that stimulus.  
Marijuana Craving Questionnaire (44) 
 A short 12-item questionnaire was given to assess current craving for cannabis. Participants 
completed the MCQ immediately after the attentional bias task; approximately 35 minutes post-drug 
and taking approximately 2 minutes. The MCQ is reliable for assessing craving in cannabis users not 
seeking treatment. 
Procedure 
Experimental sessions occurred on four occasions each separated by a one-week washout to minimize 
carry-over effects (>3 times elimination half-life of THC (6)). On each (identical) session, 10 minutes 
after drug administration, participants completed the BSS to assess cannabis related state satiety (T1), 
they completed the dot probe task to assess appetitive cue salience at 25 minutes post-drug 
administration, the MCQ at 35 minutes and the BSS again (T2) at 70 minutes post-drug administration.   
The full test battery took approximately 1.5 hours on each test day. Other tasks conducted during the 
session are reported elsewhere (6, 33). Acute drug effects were monitored throughout the session 
(see supplementary figure 1 reproduced from (6)).  Participants were reimbursed £120 for their time 
on the last testing day and debriefed fully. All participants provided written, informed consent on each 
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occasion and ethical approval was given by the UCL Research Ethics Committee and was conducted in 
accordance with the Declaration of Helsinki.  
Statistical analysis 
All analyses were conducted with SPSS 24.0. Syntax are available from CH on request. Outliers and 
normality were assessed via diagnostic plots. Extreme outliers (>3 times interquartile range) were 
winsorized within-group to the next highest/lowest value +/- 1. Descriptive statistics (table 1) based 
on genotype were conducted with one way analysis of variance (ANOVA) and Chi-Squared tests. When 
variances were not equal between groups (assessed using Levene’s test) then unequal variances 
(Welch’s) t-tests were used.   
Analyses were completed using the general linear model repeated measures ANOVA (RMANOVA) with 
each model containing  a within-subjects factor of drug (placebo, THC, THC+CBD, CBD) and a between-
subjects factor of genotype i.e. a 4 (drug) x 2 (genotype) RMANOVA. For attentional bias, there was 
an additional within-subjects factor of stimulus type (cannabis, food) which led to a 4 (drug) x 2 
(stimuli) x 2 (genotype) RMANOVA. For BSS “want to smoke a joint”, there was additional within-
subject factor was time as the assessment was taken twice (T1 – 10 minutes post-drug, T2 – 70 minutes 
post drug) which led to a 4 (drug) x 2 (genotype) x 2 (time) RMANOVA. Greenhouse Geisser corrections 
were applied for violations of sphericity (degrees of freedom are rounded to the nearest integer Main 
effects of drug were explored with a priori simple contrasts versus placebo to reduce the number of 
comparisons (i.e. placebo vs. THC, placebo vs. THC+CBD and placebo vs. CBD). Interactions between 
factors were explored with Bonferroni-corrected pairwise comparisons locally within each omnibus 
term. The main factor of interest was a drug x genotype interaction. η² was calculated as the 
SSeffect/SStotal.  
Results  
Sample Characteristics (Table 1) 
CNR1 rs1049353 genotypes were in Hardy-Weinberg equilibrium (G/G=20, A/G=17, AA=5; χ2 (2)= 0.21, 
p=0.64), as was CNR1 rs806378 (C/C=18, C/T=24, T/T=3; χ2(2)=1.04, p=0.17) but there was some 
evidence that FAAH rs324420 (C/C=30, A/C=10 and A/A=4; χ2(2)=4.00, p=0.05) was not. As seen in 
table 1, participants did not differ on demographics or trait mood scales based on genotype groupings 
for CNR1 rs1049353, CNR1 rs806378, or FAAH rs324420. Genotype groups differed significantly on the 
SDS where those who were homozygote GG for the CNR1 rs1039353 SNP, had a higher cannabis 
dependence score than A carriers, but groups did not differ on cannabis use variables. Additionally, a 
significant difference was observed for FAAH rs324420 CC homozygotes who had used cannabis more 
recently than A carriers.  
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BSS “Want to smoke a joint” 
CNR1 rs1049353 (Fig 2) 
There was a drug x genotype interaction (F(3,105)=4.192, p=.008, η²=.05). The interaction was 
explored with Bonferroni-corrected pairwise comparisons which showed those with the GG genotype 
had decreased wanting to smoke a joint after both THC (p=.016; d=.52) and THC+CBD (p<.001, d=.52), 
but not CBD (p=.137, d=.31) in comparison to placebo. Those with the A allele did not experience this 
reduction after THC/THC+CBD administration (both p’s=1.000). There was a main effect of drug 
(F(3,105)=4.206, p=.007, η²=.05). Simple contrasts showed lower scores for THC (M:4.73 SE:.41, 
p=0.047) and for THC+CBD (M: 4.45, SE:.42; p=0.001), in comparison to placebo, but not for CBD (M: 
4.95, SE:.43; p=.182). There was a main effect of time (F(1,36)=12.945, p=.001, η²=.03) which showed 
that wanting to smoke a joint increased across the two time-points (p<.001). There was no main effect 
of genotype (F(1,36)= .176, p=.675, η²=0.00), there were no other two-way or three-way interactions.  
CNR1 rs806378 
There was a main effect of drug (F(3,114)=3.784, p=.012, η²=.005). Simple contrasts show lower 
wanting to smoke a joint after THC (M:4.730, SE:.40; p=.043) and THC+CBD (M:4.55, SE:.43; p=.004) in 
comparison to placebo (M=5.36, SE:.43) but no differences emerged CBD (M:5.06, SE:.43; p=.254). A 
main effect of time emerged (F(1,28)=16.069, p<.001, η²=.04) which showed that wanting to smoke a 
joint increased across the two time-points (p<.001).  There were no main effects or interactions with 
genotype.  
FAAH rs324420  
Only a main effect of time emerged (F(1,27)=11.738, p=.002, η²=.04) which showed that wanting to 
smoke a joint increased across the two time-points (p<.001).   
Attentional bias 
CNR1 rs1049353 (Fig 3) 
There was a drug x genotype interaction (F(3,120)=3.108, p=.029, η²=.03). Within the GG group, 
attentional bias was significantly lower after acute THC administration (M:4.25, SE: 4.79), in 
comparison to CBD administration (M:25.93, SE: 4.88; p=.011; d=.74), but this was not significant for 
the THC+CBD (p=.066; d=.55), or placebo (p=.291; d=.47) conditions. A carriers show no differences in 
attentional bias between drug administration conditions (p’s=1.000). No Bonferroni-corrected 
pairwise comparisons met significance between genotypes in each drug condition. There was no main 
effect of drug (F(3,120)=2.002, p=.177, η²=.20), stimulus type (F(1,40)=.232, p=.129, η²=.005) or 
genotype (F(1,40)=.723, p=.40, η²=.00) or any other two way or three way interactions.  
CNR1 rs806378 
A main effect of genotype emerged (F(1,43)=5.679, p=.022, η²=.047) which showed homozygote CC 
carriers (M:20.21, SE:2.87) had a greater attentional bias than T carriers (M:11.38, SE:2.34), regardless 
of stimuli type and drug. There was no main effect of drug (F(3,129)=1.674, p=.176, η²=.002), stimulus 
type (F(1,43)=.523, p=.474, η²=.00) or other two way or three way interactions. 
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FAAH rs324420 (Fig 4) 
A drug x genotype interaction emerged (F(3,126)=3.385, p=.020, η²=.003). Bonferroni-corrected 
pairwise comparisons reveal lower attentional bias, irrespective of stimuli, in the homozygote CC 
group (M:5.56, SE:3.71) compared to  A carriers (M:21.41, SE:5.42) after THC only (p=0.02; d=.78). No 
differences emerged between genotype groups for placebo (p=.518,d=.20), THC+CBD (p=.321; d=.32) 
or CBD (p=.261; d=.37). Within the CC group, there was a significantly lower attentional bias after THC 
in comparison to CBD (M:21.14, SE:3.81; p=.018; d=.56). There was no main effect of drug 
(F(3,126)=.418, p=.740, η²=.004) or stimulus type (F(1,42)=1.089, p=.303, η² =.002) or genotype 
(F(1,42)=.169, p=.683, η²=.001). There were no other two way or three way interactions.  
Marijuana Craving Questionnaire  
CNR1 rs1049353 
There was no main effect of drug, genotype or drug x genotype interaction. 
CNR1 rs806378 
There was no main effect of drug, genotype or drug x genotype interaction. 
FAAH rs324420 
There was no main effect of drug, genotype or drug x genotype interaction. 
Sensitivity Analysis 
We included several continuous covariates to our analyses which can be found in the Supplementary 
Materials. 
 
Discussion 
This preliminary study, to our knowledge, is the first to show that the acute effects of cannabinoids 
on addiction endophenotypes are moderated by genes encoding components of the endocannabinoid 
system. Specifically, we found drug by genotype interactions for cannabis satiety and salience of 
appetitive cues for the CNR1 rs1049353 SNP. GG carriers of rs1049353 showed increased satiety and 
lower salience of cues after THC conditions (vs. placebo/CBD) indicative of intoxication. A carriers did 
not show this suggesting A carriers may be more liable to develop CUD. In regards to CNR1 rs806378, 
we found a main effect of genotype on the salience of appetitive cues wherein CC carriers showed 
greater salience to appetitive stimuli, regardless of cue type (cannabis/food) and drug condition. This 
suggests CC carriers may be more biased to appetitive cues. Finally, in regards to FAAH rs324420, we 
found a drug by genotype interaction for the salience of appetitive cues showing that A carriers 
showed a greater bias towards appetitive stimuli in comparison to CC carriers suggesting low FAAH 
functioning is influencing automatic processes related to appetitive cues. Across all three SNPs, 
genotype did not modulate craving on the marijuana craving questionnaire. These data have 
important implications. The acute response to cannabis is thought to be a marker of the development 
of CUD and psychosis from smoking the drug(31). These results may further helps us understand the 
role of the endocannabinoid system in individual differences in risk and resilience for CUD.   
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CNR1 genes modify the binding of cannabis and endogenous cannabinoids to the CB1R, thus altering 
the signalling of the endocannabinoid system which is known to play a key role in substance use 
disorders(12, 17). In the brain, CB1Rs are found on GABAergic and glutamatergic interneurons in areas 
of the brain associated with reward processing where they regulate the mesolimbic dopaminergic 
pathway leading to modulation of dopamine release in the nucleus accumbens; a key mechanism in 
incentive salience attribution(29). In this study, CNR1 genes were found to modulate cannabis users’ 
response to acute administration of cannabinoids on putative endophenotypes such as appetitive cue 
salience(24) and satiety(30) but not craving and as such, does not support common models of 
addiction(29).  It may be that A carriers of the CNR1 rs1049353 are more liable for CUD because they 
continue to show attentional bias to appetitive cues and wanting to smoke a joint after acute 
intoxication. In contrast, the GG carriers showed reductions in these endophenotypes in response to 
THC administration, as hypothesised. However, GG carriers had greater self-reported cannabis 
dependence, but the groups did not differ on other drug use measures such as frequency of use, last 
use of cannabis or years of cannabis use. When we adjusted for frequency of use and severity of 
dependence, it had no effect on the results, suggesting that this effect was not explained by variation 
in cannabis use.  CC carriers of CNR1 rs806378 showed increased bias for both cannabis and food 
related cues regardless of drug condition suggesting that CC carriers may be more susceptible to 
appetitive cues. However, no rs806378-specific effects were seen on cannabis state satiety or craving.  
In regards to FAAH, those who are homozygote for the A allele have a 30% reduction in FAAH activity 
and are a minority of the population (5%)(17, 18), however, it should be noted that in this study, we 
combined AA and AC carriers to increase power. As a result, A carriers can be used as a human genetic 
model of elevations in anandamide which may be able to inform whether FAAH inhibitors would have 
an effect on these intermediate endophenotypes(45). Indeed, FAAH inhibitors have been shown to be 
effective for treating CUD (16). However research has also shown that those with the C allele have an 
increased risk of cannabis dependence and related endophenotypes (14, 19-21). In this study, A 
carriers showed a greater attentional bias towards appetitive stimuli in comparison to CC carriers – 
which would be consistent with some previous research suggesting this polymorphism is associated 
with emotional-motivational reactivity(46) but contradicts others(47). However, FAAH genotype did 
not modulate state satiation or craving suggesting that FAAH is modulating attentional processes 
towards motivationally salient cues, which would support previous research in anxiety disorders(47). 
This dissociation between measures is not in concordance with common models of addiction that 
suggest craving, attentional bias and satiety are related so a change in attentional bias would be 
accompanied with a change in craving(29). FAAH A carriers had significantly fewer years of cannabis 
use; but when we adjusted for this in the model, results remained unchanged. In this study, low FAAH 
functioning may be influencing the implicit processes associated with salience of drug cues but did not 
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influence satiation or craving after acute drug administration – which are arguably more explicit 
measures of CUD. 
In genetic association research, there have been equivocal findings with variants in CNR1 and FAAH 
genotypes on CUD and this study adds to the data regarding the relationship between these genes 
and CUD endophenotypes. Future research should investigate the role of genetic variants in the 
endocannabinoid system on transdiagnostic markers for mental health found in the National Institute 
of Mental Health (NIHM) Research Domain criteria (RDoC) initiative including neuroimaging and 
plasma biomarkers - which may be reliable indicators(22). Additionally, the CNR1 and FAAH SNPs 
noted in this study should be investigated in relation to other cannabis-related harms such as 
psychotic-like experiences, depression and anxiety as they have already been showed to contribute 
to psychiatric problems(48). Longitudinal studies are imperative to clarify whether genetic variation 
influences cannabis dependence – such is the focus of the ABCD study(49). Moreover, the 
development of polygenic risk scores for cannabis dependence, that can capture a wider range of 
common genetic variants, should be developed and utilised. 
Strengths and Limitations  
Strengths of this study, include a controlled design of a four-way crossover with THC, CBD and their 
combination on CUD-related outcomes. One criticism levied at GWAS is that they tend to utilise a 
dichotomous diagnostic cut off, such as CUD only (22), for which the causes are likely to be complex 
and involve many mechanisms and predictors . The NIHM RDoC initiative supports research about the 
biobehavioural dimensions that cut across these prescriptive diagnostics(50). However, such 
intermediates have remain unexplored for substance use disorders until recently. They are important 
for understanding biological pathways through which genes shape behaviour. In this study, we took 
endophenotypes that have strong theoretical and empirical clinical relevance to CUD, potentially more 
than diagnostic criteria alone, which is a key strength of this highly controlled, experimental study. 
However, the behavioural genetics approach has also been heavily criticised for its lack of replicability. 
An inevitable trade-off of this rich phenotyping approach is that the sample size of this study was small 
and there were unequal numbers of each genotype, with a small amount of missing genetic 
information. The sample size calculation was based on the effects of THC, not on genetic differences 
but we strictly corrected for multiple comparisons. Given the small cell sizes, this study was only 
powered to detect small-to-medium effect sizes. It would be important to replicate these findings with 
a larger sample size allowing for analysis of a dose-response relationship between genotype and risk. 
Therefore it is important to consider these results as preliminary. Moreover, we did not use 
prospective genotyping or account for the effects of ancestry and ethnicity. Finally, we were not able 
to externally validate the consequences of the SNPs, for example, but assessing anandamide levels in 
the plasma.  
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Conclusions 
In conclusion, we report for the first time that the genes that code for the CB1 receptor and FAAH 
enzyme are implicated in the acute CUD-related response to acute consumption of cannabinoids. This 
was found for the salience of appetitive cues and state satiety, but not for craving. These results have 
important pharmacogenetic implications in regards to recreational users of cannabis who may be 
more vulnerable to the effects of THC and who may therefore be at greater risk of transitioning into 
CUD. 
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Table 1: Means (SD) for demographic, mental health and cannabis use variables for each of the genotype groups.  
 
Notes: a - Welch’s Test, b Includes White Other, mixed white and black Caribbean, mixed white and black African, any other mixed background, Asian/British 
Asian, any other Asian/British Asian background, Black/British Caribbean, Chinese and any other ethnic group, * indicated significant difference at p ≤0.05 
 
 
CNR1 rs1049353 
 
CNR1 rs806378 
 
FAAH rs324420 
 
 
GG AA/AG Test statistic CC CT/TT Test Statistic  CC AA/AC Test statistic  
Total N  
(N female) 
20 
(7) 
22  
(6) 
χ2(1)=.293, ns 18  
(6) 
27  
(8) 
χ2(1)=.069, ns 30  
(7)  
14  
(7) 
χ2(1)=3.129, ns 
Age 21.90 
(1.94) 
21.59 
(1.94) 
F(1,40)=.265, ns 21.44 
(1.98) 
22.00 
(1.79) 
F(1,43)=.953, ns 21.87 
(1.92) 
21.79 
(1.72) 
F(1,43)=.018, ns 
Race/Ethnicity (self-reported) 
        
White British 14 17 
 
12 20 
 
23 8 
 
Other Ethnic Group 6 5 χ2(1)=.28, ns 6 7 χ2(2)=.005, ns 7 5 χ2(1)=1.03, ns 
Frequency of 
cannabis use 
19.75 
(10.95) 
17.72 
(10.21) 
F(1,40)=.394, ns 20.36 
(10.15) 
17.98 
(10.82) 
F(1,43)=.548, ns 19.53 
(17.21) 
17.21 
(10.21) 
F(1,42)=.452, ns 
Severity of 
Dependence 
4.05 
(3.62) 
2.09 
(2.21) 
F(1,40)=4.585,p=0.038
* 
3.55 
(3.70) 
2.56 
(2.47) 
F(1,43)=1.187, ns 3.47 
(3.26) 
1.71 
(2.16) 
F(1,42)=3.345, ns 
Last use of cannabis  3.25 
(3.17) 
7.81 
(25.09 
F(1,40)=.652, ns 2.94 
(1.98) 
8.00 
(23.14) 
F(1,43)=.848, ns 2.63 
(1.87) 
13.43 
(31.67) 
W(1,12)=1.624, nsa 
Years of cannabis 
use  
6.80(2.31
) 
6.02 
(3.05) 
F(1,40)=.854, ns 6.00 
(2.57) 
6.31 
(2.91) 
F(1,43)=.138, ns 6.83 
(2.64) 
4.96 
(2.68) 
F(1,42)=3.557,p=.035
* 
SPQ total 19.05 
(12.41) 
16.55 
(15.86) 
F(1,40)=.320, ns 19.83 
(13.43 
15.15 
(14.32) 
F(1,43)=1.214, ns 14.07 
(9.92) 
22.36 
(19.46) 
F(1,42)=3.542, ns 
BDI  13.30 
(9.42) 
7.91 
(8.87) 
F(1,40)=3.651, ns 11.96 
(10.79) 
8.48 
(8.25) 
F(1,43)=1.485, ns 9.23 
(9.16) 
10.79 
(10.32) 
F(1,42)=.253, ns 
STAI  43.50 
(11.40) 
40.41 
(8.81) 
F(1,40)=.976, ns 42.44 
(11.55) 
40.04 
(9.63) 
F(1,43)=.575, ns 40.47 
(10.95) 
42.14 
(10.95) 
F(1,42)=.239, ns 
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Figure legends  
Figure 1. Trial structure for the visual probe task. Example of Cannabis (right) and matched neutral stimuli (left) provided 
Figure 2: Mean (±Standard Error) of the single item of the Bodily Symptoms Scale: “want to smoke a joint” averaged across the two time-points. Bonferroni 
corrected p values are displayed for the drug x genotype interaction.  Homozygote GG carriers of CNR1 rs1049353 showed reduced wanting after both THC 
measures, but A carriers show no such reduction in state satiety.   
Figure 3: Mean (±Standard Error) attentional bias, as assessed by the dot probe task, to drug and food stimuli (ms) after drug administration for each genotype 
group. Bonferroni corrected p values are displayed for the drug x genotype interaction.  CNR1 rs1049353 “A” carriers’ attentional bias remains relatively 
constant whilst GG homozygotes vary by cannabinoid administration.  
Figure 4: Mean (±Standard Error) attentional bias, as assessed by the dot probe task, after drug administration for each genotype group for FAAH rs324420. 
Bonferroni corrected p values are displayed for the drug x genotype interaction. FAAH rs324420 “A” carriers’ attentional bias remains relatively constant whilst 
CC homozygotes vary by cannabinoid administration.  
 
 
